Viral Conjunctivitis Drugs Market Trends, Outlook and Opportunity Analysis 2018-2026

Viral conjunctivitis is an inflammation of the conjunctiva, which is a thin outermost layer of the sclera and inner layer of eyelid. Viral conjunctiva is caused due to infections from virus such as adenovirus, herpes simplex virus, varicella zoster virus, picornavirus, poxvirus, and human immunodeficiency virus. It is also called as Pinkeye disease. Viral conjunctivitis is characterized by the reddish eye, watery discharge from eye, and itching/irritation. Persistent conjunctivitis from virus may lead to corneal keratitis. Treatment for viral conjunctivitis may be symptomatic or virus specific.

Treatment can include artificial tear drops to lower the dryness and irritation from infection, vasoconstrictors to reduce eye redness, decongestants to reduce the swelling, and antihistamines to reduce itching. Treatments usually are continued for one to two weeks, depending on the severity of the infection. Anti-viral therapy is utilized to treat infections from herpes simplex and varicella zoster virus.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1281

New drugs development in the U.S. to propel growth of the viral conjunctivitis market:

According to study published in the journal Ophthalmology in December 2017, approximately 80% of conjunctivitis cases in the U.S. are associated with viral conjunctivitis. According to study published in Review of Ophthalmology in January 2017, around 15 per 1000 population in the U.S. suffer from viral conjunctivitis. As per a study in Review of Optometry in 2016, an estimated 20,000 new cases, 48,000 cases of recurrences, and prevalence of 4,00,000 cases of herpes simplex keratitis were reported every year in U.S. Considering this facts, U.S. is expected to dominate the viral conjunctivitis drugs market. Also, increasing investment for development of new drugs to treat the viral conjunctivitis are further expected to propel the viral conjunctivitis drugs market growth. For instance, APD-209 is a drug candidate from Adenovir Pharma AB to treat epidemic keratoconjunctivitis from adenovirus, which has completed the phase 2 clinical studies in 2016. There is also increased awareness amongst patients about approaching the ophthalmologist to treat viral conjunctivitis.

However, there is no direct anti-viral treatment available yet for conjunctivitis, which if available may open new opportunity in viral conjunctivitis drugs market. To treat viral conjunctivitis often it becomes difficult to clinically differentiate the viral conjunctivitis from the bacterial conjunctivitis which leads to miss diagnosis. Many physicians at primary care centers prescribe antibiotic to treat viral conjunctivitis due to miss diagnosis and this chain of events limits the expansion of viral conjunctivitis drugs market. According to 2017 study in Ophthalmology, an estimated 83% patients of acute conjunctivitis visited primary care centers instead of ophthalmologist, which leads to overlap of diagnosis and treatment of viral conjunctivitis in turn restraining market growth.

Major Key Players:

Key players operating in the viral conjunctivitis drugs market include Bausch & Lomb, Allergan plc, Shire plc, NicOx S.A, NovaBay Pharmaceuticals, Inc., NanoViricides, Inc., Novartis International AG, Adenovir Pharma AB, Panoptes Pharma GES.M.B.H., Akorn Pharmaceuticals, and Quidel Corporation. Market players are investing in research to development of novel therapies to treat viral conjunctivitis.

Request For Customization of Research Report @https://www.coherentmarketinsights.com/insight/request-customization/1281

NiCox S.A. in March 2017, received the FDA approval for its ZERVIATE1 (cetirizine ophthalmic solution 0.24%) as New Drug Application (NDA), which is the first antihistaminic topical ocular formulation for the treatment of itching due to allergic conjunctivitis. Company is looking to commercialize the product in the U.S. through partnership. In 2015, Shire plc announced acquisition of Foresight Biotherapeutics for US$ 300 million. Foresight Biotherapeutics has experimental eye drop FST-100 in its pipeline, which is a combination of 0.6% povidone iodine and 0.1% dexamethasone to treat both viral and bacterial conjunctivitis. This acquisition would add growth to Shire plc’s ophthalmic portfolio.

Viral Conjunctivitis Drugs Market Taxonomy:

On the basis of drug class:

• Artificial tears
• Decongestants
• Anti-histaminic
• NSAIDS
• Anti-Viral drugs

On the basis of the distribution channel:

• Hospital Pharmacy
• Retail Pharmacy

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Diabetic Foot Ulcers Treatment Market Global Trends and Forecast to 2025

Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the patients with diabetes mellitus and diabetes insipidus, which also leads to chronic foot wounds due to minor trauma or pressure. The treatment for diabetic foot ulcers is divided into five stages: stage 1, which is a normal foot; stage 2, high risk foot; stage 3, an ulcerated foot; stage 4, an infected foot; and stage 5, a necrotic foot. It is important to prevent the development of diabetic foot ulcers in stage 1 and 2 while stage 3 require urgent treatment management for foot ulcers.

Browse Complete Report For More Information @ http://bit.ly/2LubvPB

Rising prevalence of diabetes is a major factor driving growth of the diabetic foot ulcers treatment market. As According to WHO, The number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. According to a report published by Center for Disease Control and Prevention in 2017, over 100 million of the adults in the U.S. are suffering from prediabetes or diabetes. The report has also stated that another 84.1 million have prediabetes conditions, which if not treated may lead to type 2 diabetes within five years. Furthermore, the CDC stated that between 60% and 70% of the people with diabetes suffers from diabetic neuropathy annually, where the nerves of the feet and legs are mostly affected.

The global diabetic foot ulcers treatment market was valued at US$ 1,209.4 million in 2017 and is expected to witness a robust CAGR of 9.4% over the forecast period (2017–2025).

Rising prevalence of diabetes is expected to favor growth of the diabetic foot ulcers treatment market in the near future

North America accounted for the largest share in the global diabetic foot ulcers treatment market, followed by Europe, in 2017. This is attributed to increasing prevalence of diabetes in North America. According to Center for Disease Control and Prevention, diabetes was the seventh leading cause of death in the U.S. in 2015 and 1.5 million new cases of diabetes were diagnosed among people aged 18 years and older.

Furthermore, CDC partnered with various organizations to launch programs to create awareness about diabetes. For instance, CDC established National Diabetes Prevention Program in 2010, which provides a framework to prevent or delay type 2 diabetes efforts in the U.S., where this program is still active and effective.  

Market Dynamics

Diabetic foot ulcers treatment market is mainly driven by increasing prevalence of diabetes. According to World Health Organization, it was estimated that 422 million adults were suffering from diabetes, in 2014 globally. Furthermore, according to National Diabetes Statistics Report 2017, 30.3 million people in the U.S. have been estimated to have diabetes. This is expected to favor growth of the diabetic foot ulcers treatment market.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1357

Some major players operating in the global diabetic foot ulcers treatment market include 3M Healthcare, Coloplast A/S, B.Braun Melsungen AG, Acelity L.P. Inc., Smith & Nephew Plc., Medtronic Plc, ConvaTec Inc, and Mölnlycke Health Care.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Low Molecular Weight Heparin Market - Size, Share, Outlook, and Opportunity Analysis 2018-2026

Low Molecular Weight Heparins (LMWH) are a form of pharmacological anticoagulant intervention which are derived from UFH by chemical or enzymatic depolymerisation to yield fragments that are around one third the size of heparin. Low molecular weight heparin is used for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectrum of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction. LMWHs are However, it is associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, as compared to unfractionated heparin (UFH), for thromboembolic indications. Low molecular weight heparin is the most suitable anticoagulant in case of complicated pregnancy, as it eliminates risk of crossing the placental membrane.

Browse Complete Report For More Information @ http://bit.ly/2JeLsJq

The global low molecular weight heparin market size was valued at US$ 2,882.6 Mn in 2017, and is expected to witness a CAGR of 6.7% during the forecast period (2018 – 2026).

Increasing Advantages of Low Molecular Weight Heparin over Unfractionated Heparin is expected to drive the Market Growth during the Forecast Period

Unfractionated heparin or standard heparin varies in action from patient to patient. Thus, it can only be administered to hospitalized patients under monitoring, while low molecular weight heparins (LMWHs) can be used subcutaneously once a day, without requirement for monitoring.

Furthermore, LMWHs have more predictable pharmacokinetic properties as compared to unfractionated heparin (UFH), which allows LMWHs to be administered in fixed doses and without the need for dose adjustment based on laboratory monitoring.

Market Dynamics

Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for LMWH. For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), February 2018; the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S.

Furthermore, increasing engagement of government healthcare regulatory bodies in developing and delivering effective and cost-effective low molecular weight heparin molecule products in the market is expected to propel the growth of the market. For instance, in 2014, American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal patients thereby supporting the development and use of nationally standardized concentrations of heparin when used for maintenance and flush of peripheral and central venous lines in neonatal patients.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1491

Key players operating in the low molecular weight heparin market include, Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Adrenocortical Carcinoma Treatment Market - Trends, Outlook, and Opportunity Analysis, 2018-2026

Adrenocortical carcinoma is a rare cancer affecting the outer layer of the adrenal glands, which are responsible for producing certain hormones and maintaining optimum blood pressure levels. Adrenocortical carcinoma is relatively frequent in children compared to other cancers, although the cancer may also affect adults. The most common symptoms of adrenocortical carcinoma include abdominal pain, hypertension, weight gain, and frequent urination, which are mainly caused due to tumors causing excess secretion of hormones from the adrenal glands. Mitotane is the only drug approved by the U.S. Food and Drug Administration (FDA) and European Medicine Executive Agency (EMEA) for treatment of metastatic adrenocortical carcinoma. According to the study by HealthLine Media, 2017, about 5-10% of the adrenal tumors are malignant. Diagnosis of adrenocortical carcinoma is based on urine tests, dexamethasone suppression test for detecting abnormal levels of cortisol, which is the hormone released by the adrenal glands. Also, a wide number of imaging devices are used for diagnoses of the disease, which includes CT scan, MRI, PET scan, and MIBG Scan, thus aiding for faster disease identification that aids the doctors to decide for further treatments.

Request Sample Copy of Research Report @https://www.coherentmarketinsights.com/insight/request-sample/1551

Adrenocortical Carcinoma Treatment Market: Market Dynamics

Increasing incidence of adrenocortical carcinoma associated with genetic disorders is a major factor augmenting growth of the adrenocortical carcinoma treatment market. According to the Journal of Clinical Endocrinology & Metabolism, 2013, the peak incidence of adrenocortical carcinoma ranges between 40-50 years, where women are 55–60% more likely to get affected with a ratio of ratio 1.5:1. The study also states that adrenocortical carcinoma is a rare and highly aggressive malignancy with an annual incidence of 0.05–0.2% or 1-2 cases per million population globally. Also, inherited disorders such as Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syndrome (BWS), and Carney complex are linked with increasing incidence of adrenocortical carcinoma. According to the survey by Endocrine Society, 2014, adrenocortical carcinoma comprises an approximate 3% to 10% of malignancies in LFS and over 5-15% of malignancies in BWS. Moreover, according to the study by Medscape, 2017, adrenocortical carcinoma accounted for 0.02-0.2% of all cancer-related deaths, globally.

Adrenocortical Carcinoma Treatment Market: Regional Dynamics

Regional segmentation of the global adrenocortical carcinoma treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global adrenocortical carcinoma treatment market over the forecast period, owing to rise in prevalence of the disease and presence of key players that are focusing on developing novel products, followed by Europe, the next dominating adrenocortical carcinoma treatment market. According to the National Institutes of Health Office of Rare Diseases Research, the incidence rate of adrenal cancer is about 600 new cases per year in the U.S. Moreover, organizations such as the University of Michigan Rogel Cancer Center are involved in stem cell research, to advance treatment in adrenal cancer.

Latin America is expected to gain significant traction in the forecast period, owing to higher incidence rate of the condition in Brazil. According to the survey ACC C.U.R.E. Organization, adrenal cancer in Brazil is 15 times more prevalent than any other countries in the world, attributed to high prevalence of mutation of a single gene TP53. Also, according to the Endocrine Society, 2014, the incidence during childhood is 2.9 to 4.2 per million per year in Brazil compared with an estimated incidence of 0.2 to 0.3 per million children per year worldwide. Moreover, the University of Michigan has been collaborating with the Adrenal Cancer Group in Sao Paulo to bring about the advancements in adrenal cancer research, thus providing better clinical outcomes for patients in the region.

Adrenocortical Carcinoma Treatment Market: Competitive Analysis

Manufactures are focused on launching novel therapeutic products for treatment of these rare diseases, thus accelerating market growth. For instance, in 2017, the FDA approved immunotherapy drug Keytruda (Pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy, developed by Merck & Co., indicated for advanced adrenocortical carcinoma.

Key players operating in the global adrenocortical carcinoma treatment market include ArQule, Inc., EnGeneIC Ltd., Exelixis, Inc., Merck & Co., Millendo Therapeutics, and Orphagen Pharmaceuticals, Inc.

Browse Complete Report For More Information @ http://bit.ly/2RELCO9

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Medical Supplies Market - Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

The medical supplies industry consists of companies engaged in the manufacturing and distribution of basic medical products such as surgical knives, forceps, gloves, syringes, bandages and dressings, medical laboratory equipment, stethoscopes, dental drills, x-ray films, veterinarian instruments, and other related supplies. The medical supplies excludes manufacturing and distribution of high-tech medical equipment and retail sales of drugs. Several strategies are adopted by the vendors of this industry to optimize profits. The companies with equipment supplies such as interventional cardiology devices and dental devices require extensive capital expenditures and revenue generation for their existence in the market. Their products are high-tech and large amount is spend on research and development activities to maintain a steady rollout of new offerings. However, profitability of the companies that supply disposable items such as syringes and surgical gloves is dependent on procedure volume, particularly in hospitals and therefore, does not require substantial amounts of capital expenditures. Therefore, availability of technologically advanced as well as more effective products and rise in investment in healthcare sector is fueling the market growth.

Browse Complete Report For More Information @ http://bit.ly/2ZJLtMe

Medical Supplies Market Drivers

Increasing volume of hospitals, surgical, and outpatient procedures, and upgradation and enforcement of infection prevention standards is expected to increase the adoption of medical supplies over the forecast period, thereby driving growth of medical supplies market. For instance, in 2012, Kuwait Ministry of Health and Public Works announced a grant of US$ 4.4 billion to replace and expand nine operating hospitals, which is expected to provide additional 5,400 beds, 150 operating rooms, and 500 outpatient clinics. This is expected to create a conducive environment for growth of the market.

Increasing number of patients who require long-term therapy or surgery, drug delivery, and related products is expected to increase the demand for medical supplies, in turn driving growth of the market. The usage of safety-enhanced devices for the minimally invasive delivery of parenteral medicines, IV solutions, and inhalation therapies will lead to the growth of the market. The rising prevalence of chronic conditions such as cancer, heart disorders, neurological disorders, and gynecological disorders will lead to an increase in the number of hospitalizations, thereby increasing the demand for medical supplies. For instance, according to the CDC foundation, in 2015, around 800,000 people in the U.S. died due to stroke and other cardiovascular diseases. By the ageing demographic, there is a huge drive to develop devices that can both help the treatment of age-related conditions and early diagnosis chronic diseases. According to United Nations Organization, there are an estimated 962 million people aged 60 or over in the world in 2017, comprising 13% of the global population and this population is continuously growing at a rate of about 3 per cent per year. Currently, Europe has the greatest percentage of population aged 60 or over (25%) in the same year.

Medical Supplies Market Restraints

This market is fragmented with various large to small scale players, thus competition is very high among players to compete with. Vendors continuously cutting prices on legacy products to retain the market share and support production volume and net profit. Majority of the disposable products that are not protected by patents are more likely to open to competition. Thus all these factors may restraint the overall market growth to some extent. To overcome these factors, competitors need to improve their products that are already present in the market through technologies and might boost R&D spending to overcome any technology shortcomings.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1633

Medical Supplies Market - Regional Analysis

On the basis of region, global medical supplies market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Demand for medical supplies in the Western Europe, U.S., Japan, and most other developed countries will increase at a slow pace, as their medical supplies are already well established and have adopted stringent infection prevention standards to meet the health care needs of people. By contrast, growth in the BRIC (Brazil, Russia, India, and China) countries and many other emerging economies expected to spur as health care sectors are modernized, expanding, and adapting to formal infection prevention protocols.

Medical Supplies Market – Competitive Landscape

Some of the key players operating in the medical supplies market include B. Braun Melsungen AG, Becton, Dickinson and Company, Cardinal Health, Inc., Halyard Health, Inc., Johnson & Johnson, Thermo Fisher Scientific Inc., Boston Scientific Corporation, Baxter International Inc., and 3M Company among others. Key players are adopting inorganic growth strategies such as merger and acquisition to retain their position in the market. For instance, in 2017, Becton Dickinson completed the acquisition of C.R. Bard, Inc., both companies will lead a position to improve the treatment of disease for patients and the process of care for health care providers. Furthermore, in April 2018, B. Braun Melsungen AG started five new and enhanced production plants and other administrative buildings in Penang to manufacture medical devices for infusion therapy and surgical instruments for the treatment of patients in Malaysia and across the world.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Cell Therapy Manufacturing Market - Industry Insights, Trends, Outlook and Opportunity Analysis, 2018-2026

Cell therapy is one of the most promising healthcare procedure for restoration of damaged tissue. Cell therapies have huge potential for the wide range of disease treatment including tissue degradation, immune deficiency, metabolic disorders, and cancer. Cell therapy are categorized into two type’s allogeneic (cells from third party donor) and autologous (cells from one’s own body). Cell therapy has gained significant traction in recent past and currently it under commercial development. Main objective of cell therapy is to re-establish the lost function of tissues and cells rather than to produce a new organ. Some cell therapies have been established and permitted for clinical trial. For instance, in 2013 a stage 2 clinical trial was completed for transplantation of bone marrow derived stem cells in affected knee by rheumatoid arthritis. The growth of this technique is also increased due to involvement of the government agencies. For instance, innovate U.K. 2014 report showed that government agreed to fund US$15.3 million in cell therapy manufacturing market.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1728

Cell Therapy Manufacturing Market Dynamics

Increasing number of surgical procedures performed across the world coupled with increasing number of trauma and accidents is propelling demand for new medical therapy. For instance, according to a 2015, World Health Organization (WHO) report, more than 50,000 stem cell transplants are carried out annually worldwide for various surgeries. Stem cells transplantation is promising medical therapy for patients with advance stage diseases like Alzheimer’s, arthritis, autism, blindness, cancer, cerebral palsy, diabetes etc. Key biopharmaceutical companies are majorly investing in research for cell therapy. For instance, Longeveron LL, a biopharmaceutical company received a US$ 750,000 grant from the Maryland Technology Development Corporation (TEDCO) in 2018 for stem cell therapy research. These collaborations and government funding are boosting growth of the cell therapy manufacturing market. However, the strict regulations, guidelines, and various health safety concerns over cell therapy treatment are restraining growth of the cell therapy market.

Cell Therapy Manufacturing Market - Regional Insights

On the basis of the region, the global cell therapy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global cell therapy manufacturing market, owing to large number of surgeries performed in the region as well as development of technologically advanced products for therapy. According to the National Health Statistics Report by the Centers for Disease Control & Prevention (CDC), around 201,748.3 million surgical and non-surgical procedures were performed in the U.S. in 2011.

Furthermore, Asia Pacific is projected to witness significant growth in the global cell therapy manufacturing market in the near future. Marginal market share would be grabbed by the local players entering into market due to less stringent regulatory requirements and growing customer pool prone to various chronic and infectious disease such as cancer, HIV, hepatitis etc. Therefore induction of cell therapy can provide better solutions to the patient at the marginally lower cost.

Cell Therapy Manufacturing Market - Competitive Insights

The key player operating in the global cell therapy manufacturing market include, Pharmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec. Key players are adoption growth strategies such as collaborations, introduction of new technologies and devices to maintain dominant position in the market. For instance, in 2014, ViaCyte, Inc. successfully implanted VC-01 an embryonic stem cell derived islet for the treatment of type 1 diabetes.

Browse Complete Report For More Information @ http://bit.ly/2RBeQgZ

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Linear Accelerators for Radiation Market - size, Share, Outlook and Opportunity Analysis 2018-2026

A linear accelerator is commonly used in external beam radiation treatments, for patients with cancer. Linear accelerator customizes high energy x-rays or electrons depending on a tumor’s shape and destroys cancer cells while sparing surrounding normal tissue. It is designed with build-up safety features to ensure that it will not deliver a higher dose than prescribed. The linear accelerator is used to treat all parts or organs of the body, by delivering high-energy x-rays or electrons to the region of the patient's tumor. A radiation oncologist prescribes the appropriate treatment volume and dosage of radiation. Furthermore, the medical physicist and the dosimetrist determine how to deliver the prescribed dose and calculate the amount of time it will take the accelerator to deliver that dose. Then, radiation therapists operate the linear accelerator and give patients their daily radiation treatments.

Browse Complete Report For More Information @ http://bit.ly/2Yfw0Dd

Linear Accelerators for Radiation Market Drivers

Increasing number of initiatives by various government and private organizations in early diagnosis of cancer, increases the survival rate, and reduces cancer mortality rate, and this is expected to help to boost market growth of linear accelerators for radiation. For instance, in February 2017, World Health Organization (WHO) proposed new guidelines to improve survival rate of people living with cancer, by ensuring that health service providers can focus on diagnosing and treating the disease earlier. WHO proposed three steps to early diagnosis are: improve public awareness of different cancer symptoms, invest in strengthening and equipping health services and training and ensuring people living with cancer can access safe and effective treatment. Moreover, Cancer Research UK organized Early Diagnosis Research Conference in February 2017, to share and discuss latest developments in early diagnosis research.

Growth of the linear accelerators for radiation market size is driven by increasing prevalence and incidence of various types of cancer, along with growing patient awareness programs by government and private organizations, and rising adoption of radiotherapy in cancer treatment. For instance, according to the Cancer Atlas: 2017, there were an estimated 14.1 million new cancer cases in 2012. Moreover, India, China, and other East and Central Asian countries accounted for nearly half of world’s new cancer cases and deaths, in 2017. Furthermore, according to the same source, by 2025, there will be an estimated 19.3 million new cancer cases and 11.4 million cancer deaths, in less developed regions.

Linear Accelerators for Radiation Market Restraints

Major concerns of affordability and accessibility for the treatment, lack of trained personnel to operate linear accelerators, are some of the limiting factors, which may hinder the future market growth for linear accelerators for radiation.

Linear Accelerators for Radiation Market – Regional Analysis

Geographically, global linear accelerators for radiation market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Growing adoption of linear accelerators by prominent cancer treatment centers, worldwide; and upgrading the conventional treatment, will augment growth of the linear accelerators for radiation market, in the near future. In May 2016, Leeds Cancer Centre, a leading providers of cancer care in the U.K. updated its existing treatment equipment with eight Elekta Versa HD linear accelerators. The Versa HD linear accelerators combined with Volumetric Arc Therapy (VMAT) allows to deliver complex head and neck cancer therapy up to 42% faster. Furthermore, in November 2017, Romanian government signed for five Elekta linear accelerators, to supply the country with sophisticated radiation therapy devices. In addition, Princess Margaret Cancer Centre from Canada and Odense University Hospital from Denmark in December 2016, also ordered high-field MR-supported linear accelerator (MR-linac). Both Versa HD linear accelerator and high-field MR-supported linear accelerator (MR-linac) are manufactured by Elekta AB.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1855

Linear Accelerators for Radiation Market – Competitor

Some of the key players in the linear accelerators for radiation market include Elekta AB, Siemens Healthcare, Varian Medical Systems, Inc., Accuray Incorporated, Shinva Medical Instrument Co., Ltd., and among other.

Key players in this market are collaborating and sharing their expertise in the radiation therapy to offer comprehensive and effective solution to patients with cancer. For instance, in June 2013, Siemens Healthcare and Varian Medical Systems successfully developed and deployed a software interface that connects Varian’s ARIA oncology information system with Siemens’ ONCOR and PRIMUS accelerators and imaging systems. In September 2017, Elekta and Brainlab collaborated, to integrate the use of Elekta’s Versa HD linear accelerator and Brainlab’s ExacTrac patient positioning and monitoring technology.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Interventional Oncology Solutions Market - Size, Trends and Opportunity Analysis, 2018 – 2026

Interventional oncology is a field of medical science, which includes treatment and diagnosis of cancer and other problems related to cancer using minimally invasive procedures. Interventional oncology uses various techniques such as Ultrasound, computed tomography, X-ray, and magnetic resonance imaging (MRI) to treat tumors located in various organs of the body. Interventional oncology procedures are usually used to treat metastatic or primary cancer. These procedures can be used to treat cancer in pancreas, liver, lung, breast, prostrate, kidney, and bones. Interventional oncology procedures are segmented into two procedures i.e. diagnostic and therapeutic. Therapeutic procedures can be further categorized into ablation techniques and embolization techniques. Ablation techniques uses some form of heat to destroy tumor. Embolization Technique occludes blood vessels, which feed tumors and further destroy the tumor by means of ischemia. Both these procedures are minimally invasive and there is minimal pain, complications, and discomfort with rapid recovery.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1884

Interventional Oncology Solutions Market Drivers:-

Increasing popularity of minimal invasive procedures due to advantages such as minimal risk of infection, shorter stay in the hospitals, minimal complications, minimal pain, and faster recovery as compared to invasive surgeries, is a major factor supporting the global interventional oncology solutions market growth over the forecast period. Moreover, increasing product launches is expected to aid in growth in interventional oncology solutions market size. For instance, in 2017, Terumo Corporation, a Japan-based company, launched Quirem Spheres microspheres. This is used to treat solid liver tumors, which cannot be removed by surgery completely. Microspheres consists of a radioactive isotope Holium-166. Quirem Spheres and can also be visualized in low concentrations by means of SPECT (Single Photon Emission Computed Tomography) and MRI. This feature allows doctors to carefully assess distribution of microspheres in the organs such as liver, which enables in accurate assessment of treatment after SIRT (Selective Internal radiation Therapy) procedure. Half-life of Quirem Spheres is 26.8 hours, which means that within the first 4 days more than 90% of the radiation is delivered, which is followed by implantation procedure.

Interventional Oncology Solutions Market Regional Analysis:-

North America is expected to hold dominant position in the global interventional oncology solutions market over the forecast period. This is owing to increasing mergers & acquisition and research collaboration between manufacturers and universities in the region to develop novel products. For instance, in 2015, Boston Scientific enhanced its interventional oncology portfolio by acquiring spherical embolic technologies, Embozene and Oncozene microspheres, which were developed by Celo Nova Biosciences. These spheres are designed to prevent flow of blood to the targeted tissue and also reduce growth of tumors. Moreover, in 2016, Philips collaborated with Yale School of Medicine to bring new innovations in the field of interventional oncology. Liver cancer is one of their main focus areas, as TACE (Trans arterial Chemoembolization), an alternative and minimally invasive technique to treat liver cancer patients, it has shown better results than chemotherapy. TACE is a minimally invasive procedure which is performed in interventional radiology to restrict a tumors blood supply. Small embolic particles which are coated with chemotherapeutic drugs are injected through a catheter into the arteries which supply blood to the tumor. Chemotherapeutic drugs block the supply of blood and induce cytotoxicity i.e. attacking the tumor in several ways. TACE involves administration of embolic beads and chemotherapy agents to gradually block arteries feeding the tumor, which further causes death of the tumor.

Browse Complete Report For More Information @ http://bit.ly/2Li7Fcs

Interventional Oncology Solutions Market Key Players:-

Key players operating in the global interventional oncology solutions market include Boston Scientific Corporation, Angio Dynamics, C.R. Bard, Best Medical International, Pfizer, MedWaves, Health Tronics, Sitex, BTG, Merit Medical Systems, Perseon, Cook Medical, Accuracy, Vascular Solutions, TERUMO, ALPINION MEDICAL SYSTEMS, Varian medical, Smith & Nephew, Profound Medical, BOVIE MEDICAL, and Baylis Medical.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Biomedical Sealant Market – Trends, Outlook, and Opportunity Analysis, 2018 – 2026

Biomedical sealants have emerged as a promising product for replacing staples and sutures to prevent liquid and air leakages after and during surgeries. Surgical sealants are made from synthetic or natural polymers or a combination of both. Sealant materials are required to be elastic and compliant with the tissue to allow movement and function of various tissues of lungs, blood vessel, skin, and heart.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1936

These materials include polyurethane, glycol, and polyethylene glycol or naturally occurring polysaccharides or proteins. Polyurethane is used in biomedical sealants due to its property of strong adhesion and high elasticity to tissues. Polyethylene glycol in sealants is widely used as hemostatic adhesive and fluid barrier.

Synthetic biomedical sealants have higher mechanical strength and tissue bonding properties as compared to natural biomedical sealants. These physical properties and adhesion strength are some key factors of implementing biomedical sealants to seal the wound area without causing any hindrance to the function and movement of tissues. Surgical sealants are used commonly to prevent leakage of any fluid or air from a surgical incision.

Biomedical Sealant Market Drivers:-

Approval of new biomedical sealants in key regions such as Europe is expected to drive growth of the biomedical sealant market. For instance, in 2017, Starch Medical, marketer and manufacturer of polysaccharide-based hemostatic products such as biomedical sealants was approved by C.E. Mark for Super Clot. Post the approval, company has planned to utilize their existing network of distribution partners along with their new strategic partners to bring Super Clot to hospitals and surgical teams throughout Europe. This strategic planning of product distribution is expected to fuel growth of the global biomedical sealant market.

Mergers and acquisitions by key players is also another factor expected to support the global biomedical sealant market growth. For instance, in January 2018, Baxter International Inc., a U.S.-based healthcare company, acquired two surgical products i.e. Recothrom and Preveleak of Mallinckrodt Pharmaceuticals—a producer of specialty pharmaceutical products. Recothrom is a thrombin based topical product, which is designed to assist hemostasis, this product is used when surgical methods to prevent flow of blood is ineffective in adults and pediatrics. Preveleak is a surgical sealant used to close suture holes to obtain hemostasis during surgical vascular reconstructions.  

Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1936

Non-availability of one sealants, which provide stiffness, elasticity, and high adhesion together, is a major restraining factor for growth of the market. For instance, though fibrin-based sealants do offer good elasticity, these offer low stiffness and adhesion. Cyanoacrylates have high adhesion and stiffness, however, offer low elasticity. These factors could negatively impact growth of the market over the forecast period.

Biomedical Sealant Market Regional Analysis:-

North America is expected to be dominant in the global biomedical sealant market over the forecast period. This is due to increasing product launches by key players in the region. For instance, in 2017, Starch Medical, a marketer and manufacturer of polysaccharide-based hemostatic products such as biomedical sealants, launched its new product Super Clot. Super Clot is a biomedical sealant used for effective and rapid hemostasis. Such new products in the market are expected to boost growth of the North America biomedical sealant market.

Europe biomedical sealant market is also expected to exhibit significant growth over the forecast period. This is due to increasing number of approvals for new products by Certification Marking (C.E. Mark). For instance, in 2017, Gecko Medical, a medical device company which develops innovative polymers to support reconstruction of tissue, announced C.E mark approval for its product SETALUM sealant.

SETALUM sealant is bio-reabsorb able, biocompatible, and can also be used in dynamic and wet environments such as blood as an add-on to sutures during vascular surgeries. This sealant is applied to tissue in an appropriate position and is further activated using a light activation pen. This sealant is easily applicable due to its viscosity and hydrophobicity..

Biomedical Sealant Market Key Players:-

Key players operating in the global biomedical sealant include Bostik, 3M Company, Henkel AG & company, KGaA., CryoLife Inc., Chemence Ltd., Cyberbond LLC., Ethicon Inc., Covidien PLC., Glustitch Inc., Adhezion Biomedical LLC., Cohera Medical Inc., Baxter International Inc., Meyer Haake GmbH, Angiotech Pharmaceuticals Inc., and Biocoral Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com